Evidence map›Paper›PMID 30659272›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2019

High-content, cell-by-cell assessment of HER2 overexpression and amplification: a tool for intratumoral heterogeneity detection in breast cancer.

Huu Tuan Nguyen, Daniel Migliozzi, Bettina Bisig, Laurence de Leval, Martin A M Gijs

Open access · hybridAbstract read
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Huu Tuan NguyenLaboratory of Microsystems 2, École Polytechnique Fédérale de Lausanne EPFL, Lausanne, Switzerland.ORCID 0000-0001-6130-2828
Daniel MigliozziLaboratory of Microsystems 2, École Polytechnique Fédérale de Lausanne EPFL, Lausanne, Switzerland.
Bettina BisigInstitute of Pathology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Laurence de LevalInstitute of Pathology, Centre Hospitalier Universitaire Vaudois and University of Lausanne, Lausanne, Switzerland.
Martin A M GijsLaboratory of Microsystems 2, École Polytechnique Fédérale de Lausanne EPFL, Lausanne, Switzerland. martin.gijs@epfl.ch.
École Polytechnique Fédérale de Lausanne · CHUniversity Hospital of Lausanne · CH

Funding

European Research Council 320404
6 · The paper itself

Abstract

Immunohistochemistry and fluorescence in situ hybridization are the two standard methods for human epidermal growth factor receptor 2 (HER2) assessment. However, they have severe limitations to assess quantitatively intratumoral heterogeneity (ITH) when multiple subclones of tumor cells co-exist. We develop here a high-content, quantitative analysis of breast cancer tissues based on microfluidic experimentation and image processing, to characterize both HER2 protein overexpression and HER2 gene amplification at the cellular level. The technique consists of performing sequential steps on the same tissue slide: an immunofluorescence (IF) assay using a microfluidic protocol, an elution step for removing the IF staining agents, a standard FISH staining protocol, followed by automated quantitative cell-by-cell image processing. Moreover, ITH is accurately detected in both cluster and mosaic form using an analysis of spatial association and a mathematical model that allows discriminating true heterogeneity from artifacts due to the use of thin tissue sections. This study paves the way to evaluate ITH with high accuracy and content while requiring standard staining methods.

Indexed as

Gene AmplificationGene Expression Regulation, NeoplasticGenetic HeterogeneityBreast NeoplasmsCell Line, TumorErb-b2 Receptor Tyrosine KinasesFemaleFluorescent Antibody TechniqueHumansIn Situ Hybridization, FluorescenceMicrofluidic Analytical TechniquesReproducibility of ResultsERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID30659272
PMCPMC6522386
OpenAlexW2909134881

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.